Case report: Irinotecan-induced interstitial lung disease in an advanced colorectal cancer patient resurfacing decades after allogeneic bone marrow transplantation for aplastic anemia; a case report and narrative review of literature
Two mechanisms of drug-induced interstitial lung disease (DILD) have been reported: 1) direct injury of lung epithelial cells and/or endothelial cells in lung capillaries by the drug and/or its metabolites and 2) hypersensitivity reactions. In both mechanisms, immune reactions such as cytokine and T cell activation are involved in DILD. While past and present lung diseases and accumulative lung damage due to smoking and radiation are risk factors for DILD, the association between the immune status of the host and DILD is not well known. Herein, we report a case of advanced colorectal cancer with a history of allogeneic bon...
Source: Frontiers in Oncology - June 16, 2023 Category: Cancer & Oncology Source Type: research
Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial
CONCLUSION: AVA is effective and well-tolerated in NSAA patients who are refractory, relapsed, or intolerant to CsA/tacrolimus ± eltrombopag. Earlier treatment and relapsed/intolerant AA may show a better short-term response rate. More studies are needed to define the optimal dose and the long-term efficacy (NCT04728789).PMID:37318085 | DOI:10.1080/07853890.2023.2224044 (Source: Annals of Medicine)
Source: Annals of Medicine - June 15, 2023 Category: Internal Medicine Authors: Ziqi Wan Miao Chen Bing Han Source Type: research
LncRNA OBFC2A modulated benzene metabolites-induced autophagy and apoptosis by interacting with LAMP2
In conclusion, we demonstrate that lncRNA OBFC2A mediates 1,4-BQ-induced apoptosis and autophagy by interacting with LAMP2. LncRNA OBFC2A could serve as a biomarker for hematotoxicity caused by benzene.PMID:37302536 | DOI:10.1016/j.fct.2023.113889 (Source: Food and Chemical Toxicology)
Source: Food and Chemical Toxicology - June 11, 2023 Category: Food Science Authors: Jingyu Wang Yujiao Chen Xiaoli Guo Wei Zhang Jing Ren Ai Gao Source Type: research
Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy
We report on conditional survival and standardized mortality ratios (SMR), which compares the mortality risk with the general population adjusted for age, gender, and race/ethnicity, in patients with SAA alive for at least 12 months after treatment with IST or HCT between 2000 and 2018. Two treatment periods were defined a priori (2000-2010, 2011-2018), given changes to treatment regimens and differences in length of follow-up. The SMRs of patients treated during the period 2000-2010 and survived 1 year were 3.50 (95% confidence interval [CI]: 2.62-4.58), 4.12 (95% CI 3.20-5.21), and 8.62 (95% CI 6.88-10.67) after IST, mat...
Source: Haematologica - June 1, 2023 Category: Hematology Authors: Ryotaro Nakamura Bhavisha A Patel Soyoung Kim F Lennie Wong Saro H Armenian Emma M Groarke Daniel A Kessler Kyle M Hebert Michael Heim Mary Eapen Neal S Young Source Type: research
Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy
We report on conditional survival and standardized mortality ratios (SMR), which compares the mortality risk with the general population adjusted for age, gender, and race/ethnicity, in patients with SAA alive for at least 12 months after treatment with IST or HCT between 2000 and 2018. Two treatment periods were defined a priori (2000-2010, 2011-2018), given changes to treatment regimens and differences in length of follow-up. The SMRs of patients treated during the period 2000-2010 and survived 1 year were 3.50 (95% confidence interval [CI]: 2.62-4.58), 4.12 (95% CI 3.20-5.21), and 8.62 (95% CI 6.88-10.67) after IST, mat...
Source: Haematologica - June 1, 2023 Category: Hematology Authors: Ryotaro Nakamura Bhavisha A Patel Soyoung Kim F Lennie Wong Saro H Armenian Emma M Groarke Daniel A Kessler Kyle M Hebert Michael Heim Mary Eapen Neal S Young Source Type: research
Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy
We report on conditional survival and standardized mortality ratios (SMR), which compares the mortality risk with the general population adjusted for age, gender, and race/ethnicity, in patients with SAA alive for at least 12 months after treatment with IST or HCT between 2000 and 2018. Two treatment periods were defined a priori (2000-2010, 2011-2018), given changes to treatment regimens and differences in length of follow-up. The SMRs of patients treated during the period 2000-2010 and survived 1 year were 3.50 (95% confidence interval [CI]: 2.62-4.58), 4.12 (95% CI 3.20-5.21), and 8.62 (95% CI 6.88-10.67) after IST, mat...
Source: Haematologica - June 1, 2023 Category: Hematology Authors: Ryotaro Nakamura Bhavisha A Patel Soyoung Kim F Lennie Wong Saro H Armenian Emma M Groarke Daniel A Kessler Kyle M Hebert Michael Heim Mary Eapen Neal S Young Source Type: research
Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy
We report on conditional survival and standardized mortality ratios (SMR), which compares the mortality risk with the general population adjusted for age, gender, and race/ethnicity, in patients with SAA alive for at least 12 months after treatment with IST or HCT between 2000 and 2018. Two treatment periods were defined a priori (2000-2010, 2011-2018), given changes to treatment regimens and differences in length of follow-up. The SMRs of patients treated during the period 2000-2010 and survived 1 year were 3.50 (95% confidence interval [CI]: 2.62-4.58), 4.12 (95% CI 3.20-5.21), and 8.62 (95% CI 6.88-10.67) after IST, mat...
Source: Haematologica - June 1, 2023 Category: Hematology Authors: Ryotaro Nakamura Bhavisha A Patel Soyoung Kim F Lennie Wong Saro H Armenian Emma M Groarke Daniel A Kessler Kyle M Hebert Michael Heim Mary Eapen Neal S Young Source Type: research
Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy
We report on conditional survival and standardized mortality ratios (SMR), which compares the mortality risk with the general population adjusted for age, gender, and race/ethnicity, in patients with SAA alive for at least 12 months after treatment with IST or HCT between 2000 and 2018. Two treatment periods were defined a priori (2000-2010, 2011-2018), given changes to treatment regimens and differences in length of follow-up. The SMRs of patients treated during the period 2000-2010 and survived 1 year were 3.50 (95% confidence interval [CI]: 2.62-4.58), 4.12 (95% CI 3.20-5.21), and 8.62 (95% CI 6.88-10.67) after IST, mat...
Source: Haematologica - June 1, 2023 Category: Hematology Authors: Ryotaro Nakamura Bhavisha A Patel Soyoung Kim F Lennie Wong Saro H Armenian Emma M Groarke Daniel A Kessler Kyle M Hebert Michael Heim Mary Eapen Neal S Young Source Type: research
New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination
Int J Hematol. 2023 May 23. doi: 10.1007/s12185-023-03618-7. Online ahead of print.ABSTRACTVaccination with a coronavirus disease-2019 (COVID-19) vaccine is an effective public health measure for reducing the risk of infection and severe complications from COVID-19. However, serious hematological complications after COVID-19 vaccination have been reported. Here, we report a case of new-onset hypomegakaryocytic thrombocytopenia (HMT) with the potential for progression to aplastic anemia (AA) that developed in a 46-year-old man 4 days after the fourth mRNA COVID-19 vaccination. Platelet count rapidly decreased after vaccinat...
Source: International Journal of Hematology - May 23, 2023 Category: Hematology Authors: Mirei Kobayashi Akio Mori Yoshitaka Oda Emi Yokoyama Minoru Kanaya Koh Izumiyama Makoto Saito Shinya Tanaka Masanobu Morioka Takeshi Kondo Source Type: research
New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination
Int J Hematol. 2023 May 23. doi: 10.1007/s12185-023-03618-7. Online ahead of print.ABSTRACTVaccination with a coronavirus disease-2019 (COVID-19) vaccine is an effective public health measure for reducing the risk of infection and severe complications from COVID-19. However, serious hematological complications after COVID-19 vaccination have been reported. Here, we report a case of new-onset hypomegakaryocytic thrombocytopenia (HMT) with the potential for progression to aplastic anemia (AA) that developed in a 46-year-old man 4 days after the fourth mRNA COVID-19 vaccination. Platelet count rapidly decreased after vaccinat...
Source: International Journal of Hematology - May 23, 2023 Category: Hematology Authors: Mirei Kobayashi Akio Mori Yoshitaka Oda Emi Yokoyama Minoru Kanaya Koh Izumiyama Makoto Saito Shinya Tanaka Masanobu Morioka Takeshi Kondo Source Type: research
New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination
Int J Hematol. 2023 May 23:1-6. doi: 10.1007/s12185-023-03618-7. Online ahead of print.ABSTRACTVaccination with a coronavirus disease-2019 (COVID-19) vaccine is an effective public health measure for reducing the risk of infection and severe complications from COVID-19. However, serious hematological complications after COVID-19 vaccination have been reported. Here, we report a case of new-onset hypomegakaryocytic thrombocytopenia (HMT) with the potential for progression to aplastic anemia (AA) that developed in a 46-year-old man 4 days after the fourth mRNA COVID-19 vaccination. Platelet count rapidly decreased after vacc...
Source: International Journal of Hematology - May 23, 2023 Category: Hematology Authors: Mirei Kobayashi Akio Mori Yoshitaka Oda Emi Yokoyama Minoru Kanaya Koh Izumiyama Makoto Saito Shinya Tanaka Masanobu Morioka Takeshi Kondo Source Type: research
New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination
Int J Hematol. 2023 May 23:1-6. doi: 10.1007/s12185-023-03618-7. Online ahead of print.ABSTRACTVaccination with a coronavirus disease-2019 (COVID-19) vaccine is an effective public health measure for reducing the risk of infection and severe complications from COVID-19. However, serious hematological complications after COVID-19 vaccination have been reported. Here, we report a case of new-onset hypomegakaryocytic thrombocytopenia (HMT) with the potential for progression to aplastic anemia (AA) that developed in a 46-year-old man 4 days after the fourth mRNA COVID-19 vaccination. Platelet count rapidly decreased after vacc...
Source: International Journal of Hematology - May 23, 2023 Category: Hematology Authors: Mirei Kobayashi Akio Mori Yoshitaka Oda Emi Yokoyama Minoru Kanaya Koh Izumiyama Makoto Saito Shinya Tanaka Masanobu Morioka Takeshi Kondo Source Type: research
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
CONCLUSIONS: Olaparib plus bevacizumab provided clinically meaningful OS improvement for first-line patients with HRD-positive ovarian cancer. These prespecified exploratory analyses demonstrated improvement despite a high proportion of patients in the placebo arm receiving PARP inhibitors post-progression, confirming the combination as one of the standards of care in this setting with the potential to enhance cure.PMID:37211045 | DOI:10.1016/j.annonc.2023.05.005 (Source: Ann Oncol)
Source: Ann Oncol - May 21, 2023 Category: Cancer & Oncology Authors: I Ray-Coquard A Leary S Pignata C Cropet A Gonz ález-Martin C Marth S Nagao I Vergote N Colombo J M äenpää F Selle J Sehouli D Lorusso E M Guerra Alia G Bogner H Yoshida C Lefeuvre-Plesse P Buderath A M Mosconi A Lortholary A Burges J Medioni A El-Bal Source Type: research
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
CONCLUSIONS: Olaparib plus bevacizumab provided clinically meaningful OS improvement for first-line patients with HRD-positive ovarian cancer. These prespecified exploratory analyses demonstrated improvement despite a high proportion of patients in the placebo arm receiving PARP inhibitors post-progression, confirming the combination as one of the standards of care in this setting with the potential to enhance cure.PMID:37211045 | DOI:10.1016/j.annonc.2023.05.005 (Source: Ann Oncol)
Source: Ann Oncol - May 21, 2023 Category: Cancer & Oncology Authors: I Ray-Coquard A Leary S Pignata C Cropet A Gonz ález-Martin C Marth S Nagao I Vergote N Colombo J M äenpää F Selle J Sehouli D Lorusso E M Guerra Alia G Bogner H Yoshida C Lefeuvre-Plesse P Buderath A M Mosconi A Lortholary A Burges J Medioni A El-Bal Source Type: research
